3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
28
Lymphoma
13
Leukemia
11
Lymphoma, Non-Hodgkin
9
Lymphoma, Follicular
6
Lymphoma, Mantle-Cell
5
Burkitt Lymphoma
5
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma, B-Cell
3
Leukemia, B-Cell
3
Waldenstrom Macroglobulinemia
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Thrombocytopenia
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Melanoma
1
Lymphocytosis
1
Lymphadenopathy
1
Fever
1
Fatigue
1
Disease
1
Bronchiolitis Obliterans Syndrome
1
Autoimmune Diseases of the Nervous System
1
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
Agammaglobulinemia
1
Interventions
ofatumumab
1
daratumumab
1
Transcranial Direct Current Stimulation
1
Salpingo-oophorectomy
1
Rituximab
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
×
ofatumumab
×
Clear all
NCT06867991
2025-07-15
RADIA
The First People's Hospital of Changzhou
Phase 3
Recruiting
200 enrolled